JSE-listed Aspen, Africa’s largest pharmaceutical manufacturer, this week recorded positive results for the period ended December 2007.
The consumer division increased revenue by three percent and the division in SA remains vulnerable to the retail cycle. The downturn in the cycle was compounded by the discontinuation of a range of laxatives due to the banning of phenolphthalein.
